Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Seasonal flu vaccine · 2 trials · 1 indication
Immunogenicity was measured as the percentage of participants who achieved seroconversion or significant increase in single radial hemolysis (SRH) area, against each of the three vaccine strains, three weeks after vaccination (day 22), evaluated using SRH assay. Seroconversion: proportion of participants with negative pre-vaccination serum and a post-vaccination serum area ≥ 25 mm2. Significant increase: proportion of participants with at least a 50% increase in area from positive pre-vaccination serum. Seroconversion or significant increase: proportion of participants with either seroconversion or significant increase. The European (Committee for Medicinal Products for Human Use \[CHMP\]) criterion is met, if percentage of participants achieving seroconversion or significant increase in SRH area is 30% (≥65 years).
Geometric mean ratio (GMR) of participants was calculated as the ratio of post-vaccination to pre-vaccination SRH geometric mean areas (GMAs), directed against each of the three vaccine strains, three weeks after FLUAD vaccination (day 22). The CHMP criterion was met if the geometric mean increase (GMR, day 22/day 1) in SRH antibody area is \>2.0 (≥65 years).
Immunogenicity was measured as the percentage of participants achieving SRH area ≥25 mm2 against each of the three vaccine strains at baseline (day 1) and three weeks after FLUAD vaccination (day 22). This criterion is met according to CHMP guideline if percentage of participants achieving SRH area ≥25 mm2 is 60% (≥65 years).
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | No comparator is administered, only one IM single dose of trivalent subunit inactivated influenza vaccine is administered during the vaccination visit |
| Name | Type | Description |
|---|---|---|
| Seasonal flu vaccine | BIOLOGICAL | This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22) |
Key Inclusion Criteria: * Males and females volunteers of 65 years of age or older * Mentally competent * Willing and able to give written informed consent prior to study entry. * Able to comply with all the study requirements. * In general good health Key Exclusion Criteria: * Any serious chroni...
Seasonal flu vaccine is used for the prevention of seasonal influenza, a contagious respiratory illness caused by influenza viruses. It is an investigational vaccine being developed by Novartis AG (NVS) and is currently in Phase 2 clinical development. The vaccine is intended to protect against seasonal flu strains.
Seasonal flu vaccine is being developed by Novartis AG, a multinational pharmaceutical company headquartered in Basel, Switzerland. Novartis trades on the New York Stock Exchange under the ticker symbol NVS. The vaccine is currently in Phase 2 clinical trials for the prevention of seasonal influenza.
Seasonal flu vaccine is currently in Phase 2 clinical development. It is an investigational vaccine and has not yet been approved by regulatory authorities. Two Phase 2 clinical trials have been completed, with a total of 97 participants enrolled across studies conducted in Vietnam and Italy.
Seasonal flu vaccine has been studied in two completed Phase 2 clinical trials. The first, NCT01123954, evaluated the safety of a trivalent subunit inactivated influenza vaccine in 33 healthy volunteers in Vietnam. The second, NCT01152814, assessed safety and immunogenicity of an adjuvanted influenza vaccine in 64 elderly subjects in Italy.
Seasonal flu vaccine is a type of flu shot designed to prevent seasonal influenza. It is an investigational vaccine being developed by Novartis AG. While it is intended to provide protection against seasonal flu, it is still in clinical development and has not yet been approved for public use.